Search Within

Sarat Chandarlapaty

  1. "Mario Lacouture"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  2. Breast Medicine Service (7)
  3. Department of Medicine (7)
  4. Dermatology (7)
  5. Dermatology Service (7)
  6. Division of Subspecialty Medicine (7)

More Groups

People
  1. Mario Lacouture (7)
  2. Maura Dickler (5)
  3. Payal Shah (5)
  4. Anne Covey (4)
  5. Betty Ann Caravella (4)
  6. Clifford Hudis (4)

More People

Years
  1. 2022 (1)
  2. 2020 (2)
  3. 2015 (2)
  4. 2014 (2)
Publications
  1. Journal of Clinical Oncology (3)
  2. Cancer Research (2)
  3. Annals of Oncology (1)
  4. Nature Cancer (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (2)
  3. Nature Research (1)
  4. Oxford University Press (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim analysis of a single-center, single-arm, prospective phase 2 study to evaluate the efficacy and safety of benralizumab for alpelisib rash in metastatic PIK3CA-mutant, hormone receptor-positive breast cancer
    Meeting Abstract

    Lacouture, M. E.; Pan, A.; Dranitsaris, G.; Harris, U.; Chandarlapaty, S.; Dang, C. T.; Gajria, D.; Gordon, A.; Iyengar, N. M.; Robson, M. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
    Journal Article

    Razavi, P.; Dickler, M. N.; Shah, P. D.; Toy, W.; Brown, D. N.; Won, H. H.; Li, B. T.; Shen, R.; Vasan, N.; Modi, S.; more...
    Nature Cancer (2020)

    Fulltext@MSK | Save
  • EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
    Meeting Abstract

    Hurvitz, S. A.; Chia, S. K. L.; Ciruelos, E. M.; Hu, X.; Im, S. A.; Janni, W.; Jerusalem, G.; Lacouture, M.; O'Regan, R.; Rugo, H. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Hamilton, N.; Caravella, B. A.; Zamora, S.; Dang, C.; Gilewski, T.; Traina, T.; Comen, E.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Moynahan, M. E.; Modi, S.; Caravella, B. A.; Datko, F. M.; Zamora, S.; Comen, E.; Gilewski, T.; Sugarman, S. M.; D'Andrea, G.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)
    Meeting Abstract

    Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save